Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07467993 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 2
- Study locations
NCT07467993: Recruiting Phase 2 study of Schizophrenia, sponsored by Novartis Pharmaceuticals.
NCT07467993 is a Phase 2 study of Schizophrenia that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 142 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07467993, a Phase 2 study of Schizophrenia, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
Primary Outcome
PANSS is a 30-item rating scale used to assess the positive, negative, and general psychopathy symptoms of schizophrenia. PANSS total score ranges from 30 to 120 , where a higher score indicates greater severity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GXV813
Study Locations (2)
Illinois
- Uptown Research Institute LLC - Chicago
Missouri
- Arch Clinical Trials LLC - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2027-04-27 |
| Phase | Phase 2 |
What NCT07467993 shows while recruiting
NCT07467993 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07467993 reports a single indexed study location in Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT07467993 about?
NCT07467993 is a clinical study titled "Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia". The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
What is the current status of trial NCT07467993?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2026-03-16. Estimated completion is 2027-04-27.
What conditions does trial NCT07467993 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07467993?
The interventions under investigation include: Placebo (DRUG), GXV813 (DRUG).
Who is sponsoring clinical trial NCT07467993?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07467993 being conducted?
This trial has 2 study locations across Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07467993's enrollment target sits among peer trials
142 110th of 315 higher than 206 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
-
A Study of ANAVEX3-71 in Adults With Schizophrenia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI